Today: 7 February 2026
Subscribe
Browse Category

XETRA:MRK News 9 January 2026

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Immunome shares rose 7.4% to $21.97 Friday after recent Phase 3 data showed its lead drug varegacestat cut disease progression or death by 84% in desmoid tumor patients. The company plans to file for FDA approval in Q2 2026. Immunome also granted stock options to three new hires and will present at the J.P. Morgan Healthcare Conference on Jan. 14.
9 January 2026
···

Stock Market Today

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

7 February 2026
New York, Feb 7, 2026, 11:18 EST — Market closed. Mastercard Incorporated shares (MA.N) last traded down 0.6% at $548.74 on Friday, after moving between $539.90 and $556.65. The stock is about 4% below its 52-week high, according to market data. That small drop still matters because payments names like Mastercard often trade as a clean read on consumer and travel spending. Heading into the new week, the focus shifts back to U.S. growth and rate expectations, which can move the group even when company news is thin. Friday’s tape was not thin. The Dow surged 2.47% to end above
Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop